Amgen Stock Nears 52-Week High Amid Strong Investor Demand
Amgen stock is trading at an elevated level in late August 2026, nearing its 52-week high of $440.51 USD. The shares closed regular Nasdaq trading at $439.33 on August 21, 2026, surpassing the latest consensus target of $380.43 by $58.90 and representing a 15.5% gap.
The stock's current price is a result of sustained investor interest, with an intraday range between $429.38 and $440.51 on volume of 2.11 million shares. This active participation from investors reinforces the picture of a large-cap biotech that commands a premium valuation at current levels.
The company's FY 2026 EPS guidance is set at 22.300-23.500, which points to management's confidence in delivering continued profit growth from its biotechnology portfolio. The consensus analyst expectation for EPS is 22.92, sitting within the guided range but closer to its upper half.